Investment & Funding Overview

With over $50 million invested, 177 patents, and an FDA IDE already filed, the company has built a strong technological and regulatory foundation to lead a $1.6B U.S. market and a multibillion-dollar global opportunity. Guided by a Scientific Advisory Board of leading experts in complex coronary interventions, our team has developed a revolutionary coronary CTO crossing device with integrated onboard image-guidance technology.

​

This next-generation platform combines advanced imaging, a robust mechanical crossing system, and precise user-controlled navigation to improve procedural success, reduce complication rates, shorten procedure time, and lower overall equipment costs, which expands access to safe and effective CTO treatment for physicians and their patients.

​

We are now seeking strategic investment to support asset acquisition, R&D, clinical trial completion, and essential operational activities required to achieve FDA clearance within a set timeline. This funding will accelerate the advancement of a differentiated, game-changing innovation with significant clinical impact and strong investor return potential.